Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 23;13:2503–2512. doi: 10.2147/DDDT.S211051

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Yang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Downregulation of miR-23b-3p delayed the progression of OA in mice. Mice were randomly divided into three groups: control group, OA group, and OA+miR-23b-3p inhibitor group. (A) Histological analysis of OA was evaluated by Safranin O staining and hematoxylin-eosin staining. (B) Osteoarthritis Research Society International scores, (C) subchondral bone plate thickness, and (D) synovitis scores were used to measure the progression of OA. **P<0.01 compared with the control group, ^##P<0.01 compared with OA group.